Literature DB >> 32000897

Functional assay to assess T-cell inhibitory properties of myeloid derived suppressor cells (MDSCs) isolated from the tumor microenvironment of murine glioma models.

Mahmoud S Alghamri1, Neha Kamran1, Padma Kadiyala1, Pedro Ricardo Lowenstein1, Maria Graciela Castro2.   

Abstract

Despite advances in uncovering the molecular mechanisms that mediate glioma progression and the implementation of novel therapeutic modalities, patients' prognosis remains dismal. This is due to both systemic and local tumor induced immune suppression. We are particularly interested in the role played by infiltrating immunosuppressive myeloid derived suppressor cells (MDSCs) in the glioma tumor microenvironment (TME). This immunosuppressive TME also interferes with the effectiveness of immunotherapies against glioma. Development of multipronged treatment approaches is imperative when aiming to generate a robust anti-glioma immune response. Evaluating the inhibitory potential of MDSCs within the TME is an important aspect for developing effective treatments for glioma. Herein, we discuss methodology to assess the inhibitory effects of MDSCs isolated from the TME using a mouse glioma model.
© 2020 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Immunosuppression; MDSCs; T-cell inhibition; Tumor microenvironment

Mesh:

Year:  2019        PMID: 32000897      PMCID: PMC7038868          DOI: 10.1016/bs.mie.2019.05.047

Source DB:  PubMed          Journal:  Methods Enzymol        ISSN: 0076-6879            Impact factor:   1.600


  33 in total

1.  Circulating Myeloid-Derived Suppressor Cells Predict Differentiated Thyroid Cancer Diagnosis and Extent.

Authors:  Trevor E Angell; Melissa G Lechner; Alison M Smith; Sue E Martin; Susan G Groshen; Dennis R Maceri; Peter A Singer; Alan L Epstein
Journal:  Thyroid       Date:  2016-02-10       Impact factor: 6.568

2.  Immature immunosuppressive CD14+HLA-DR-/low cells in melanoma patients are Stat3hi and overexpress CD80, CD83, and DC-sign.

Authors:  Isabel Poschke; Dimitrios Mougiakakos; Johan Hansson; Giuseppe V Masucci; Rolf Kiessling
Journal:  Cancer Res       Date:  2010-05-18       Impact factor: 12.701

3.  Transposon mediated integration of plasmid DNA into the subventricular zone of neonatal mice to generate novel models of glioblastoma.

Authors:  Anda-Alexandra Calinescu; Felipe Javier Núñez; Carl Koschmann; Bradley L Kolb; Pedro R Lowenstein; Maria G Castro
Journal:  J Vis Exp       Date:  2015-02-22       Impact factor: 1.355

4.  Circulating myeloid-derived suppressor cells correlate with clinical outcome in Hodgkin Lymphoma patients treated up-front with a risk-adapted strategy.

Authors:  Alessandra Romano; Nunziatina Laura Parrinello; Calogero Vetro; Stefano Forte; Annalisa Chiarenza; Amalia Figuera; Giovanna Motta; Giuseppe Alberto Palumbo; Massimo Ippolito; Ugo Consoli; Francesco Di Raimondo
Journal:  Br J Haematol       Date:  2014-11-07       Impact factor: 6.998

5.  Increased frequency and clinical significance of myeloid-derived suppressor cells in human colorectal carcinoma.

Authors:  Hong-Li Sun; Xin Zhou; Yi-Feng Xue; Ke Wang; Yun-Feng Shen; Jing-Jue Mao; Hong-Feng Guo; Zong-Ning Miao
Journal:  World J Gastroenterol       Date:  2012-07-07       Impact factor: 5.742

6.  Therapeutic regulation of myeloid-derived suppressor cells and immune response to cancer vaccine in patients with extensive stage small cell lung cancer.

Authors:  Cristina Iclozan; Scott Antonia; Alberto Chiappori; Dung-Tsa Chen; Dmitry Gabrilovich
Journal:  Cancer Immunol Immunother       Date:  2013-04-16       Impact factor: 6.968

7.  Identification of discrete tumor-induced myeloid-derived suppressor cell subpopulations with distinct T cell-suppressive activity.

Authors:  Kiavash Movahedi; Martin Guilliams; Jan Van den Bossche; Rafael Van den Bergh; Conny Gysemans; Alain Beschin; Patrick De Baetselier; Jo A Van Ginderachter
Journal:  Blood       Date:  2008-02-13       Impact factor: 22.113

Review 8.  Myeloid-Derived Suppressor Cells: Critical Cells Driving Immune Suppression in the Tumor Microenvironment.

Authors:  Katherine H Parker; Daniel W Beury; Suzanne Ostrand-Rosenberg
Journal:  Adv Cancer Res       Date:  2015-05-12       Impact factor: 6.242

9.  Increase in CD14+HLA-DR -/low myeloid-derived suppressor cells in hepatocellular carcinoma patients and its impact on prognosis.

Authors:  Fumitaka Arihara; Eishiro Mizukoshi; Masaaki Kitahara; Yoshiko Takata; Kuniaki Arai; Tatsuya Yamashita; Yasunari Nakamoto; Shuichi Kaneko
Journal:  Cancer Immunol Immunother       Date:  2013-06-14       Impact factor: 6.968

10.  Altered recognition of antigen is a mechanism of CD8+ T cell tolerance in cancer.

Authors:  Srinivas Nagaraj; Kapil Gupta; Vladimir Pisarev; Leo Kinarsky; Simon Sherman; Loveleen Kang; Donna L Herber; Jonathan Schneck; Dmitry I Gabrilovich
Journal:  Nat Med       Date:  2007-07-01       Impact factor: 53.440

View more
  2 in total

Review 1.  Macrophages and microglia: the cerberus of glioblastoma.

Authors:  Alice Buonfiglioli; Dolores Hambardzumyan
Journal:  Acta Neuropathol Commun       Date:  2021-03-25       Impact factor: 7.801

2.  Prostate Cancer Survivors Present Long-Term, Residual Systemic Immune Alterations.

Authors:  Katalin Balázs; Zsuzsa S Kocsis; Péter Ágoston; Kliton Jorgo; László Gesztesi; Gyöngyi Farkas; Gábor Székely; Zoltán Takácsi-Nagy; Csaba Polgár; Géza Sáfrány; Zsolt Jurányi; Katalin Lumniczky
Journal:  Cancers (Basel)       Date:  2022-06-22       Impact factor: 6.575

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.